5 studies found for:    Lx1032
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate Safety and Efficacy of LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: 500 mg LX1606 QD;   Drug: 500 mg LX1606 TID;   Drug: Placebo
2 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Low Dose Part 1;   Drug: Mid-Low Dose Part 1;   Drug: Mid-High Dose Part 1;   Drug: High Dose Part 1;   Drug: Part 2 Expanded Cohort;   Drug: Placebo;   Drug: Open Label Dose Extension;   Drug: Open Label Extension 2;   Drug: Open Label Extension 3
3 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start);   Drug: Mid-low dose LX1606 - Day 15 (start);   Drug: Mid-high dose LX1606 - Day 29 (start);   Drug: High dose LX1606 - Day 43 (start);   Drug: 4-Week Open Label Dose Extension;   Drug: 72-Week Open Label Dose Extension
4 Active, not recruiting This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID;   Drug: Enalapril 10 mg BID
5 Not yet recruiting Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Condition: Chronic Heart Failure With Reduced Ejection Fraction.
Intervention: Drug: LCZ696

Indicates status has not been verified in more than two years